Bimetinib/Bemetinib Dosage Guide

Binimetinib is a targeted therapy drug mainly used to treat melanoma and non-small cell lung cancer (NSCLC) carrying BRAF V600E or V600K mutations. As a MEK inhibitor, bimetinib inhibits the proliferation of cancer cells and slows tumor growth by interfering with the functions of MEK1 and MEK2. Its specific usage and dosage guidelines are as follows.

1. Melanoma

When treating melanoma, it is necessary to first confirm whether the BRAF V600E or V600K mutation is present in the patient's tumor sample. If such a mutation is confirmed, the recommended dose of bimetinib is 45 mg orally twice daily, usually with or without food. This dose has been shown to be effective in inhibiting tumor growth and slowing disease progression.

For those patients with moderate or severe hepatic impairment, the recommended dose is 30 mg orally twice daily. This can reduce the burden of liver metabolism, avoid drug accumulation in the body, and ensure the safety of treatment.

2. Non-small cell lung cancer (NSCLC)

Similarly, when treating non-small cell lung cancer, the presence of the BRAF V600E mutation in the tumor or plasma sample must first be confirmed. If mutation-positive, the recommended dose of bimetinib is 45 mg orally twice daily in the same manner as for melanoma treatment, with or without food. With this treatment, patients can expect to slow tumor growth and improve their quality of life.

3. Taking suggestions

Whether in the treatment of melanoma or non-small cell lung cancer, patients should strictly follow the recommended dosage and medication schedule. Bimetinib needs to be taken long-term to ensure that the drug can continue to work. At the same time, patients should undergo regular liver function monitoring, especially those with liver insufficiency or other underlying diseases, to ensure safety during treatment.

Keyword tag:

Bimetinib, Bemetinib, Binimetinib, usage and dosage, melanoma, non-small cell lung cancer, BRAF V600E, MEK inhibitors, oral dosage, drug monitoring

Reference materials:https://www.medicines.org.uk/emc/product/9501/smpc